Stada

Executive Summary

STADA Arzneimittel AG is a leading German pharmaceutical company with over 130 years of history, focusing on generic medicines, consumer healthcare, and specialty pharmaceuticals. The company operates globally, offering affordable everyday health products and established consumer brands. Despite being privately held, STADA has demonstrated resilience and growth through strategic acquisitions and a robust pipeline of biosimilars and generics. In recent years, the company has expanded its international footprint, particularly in emerging markets, and has strengthened its consumer health division through brand acquisitions. The generics market faces pricing pressures, but STADA's diversified portfolio and focus on high-quality products position it well to navigate challenges. With a strong presence in Europe and growing operations in Asia and the Americas, STADA is poised for steady growth, supported by demographic trends and increasing demand for affordable healthcare.

Upcoming Catalysts (preview)

• Q4 2026Biosimilar Launch of Adalimumab in Key European Markets85% success
• Q2 2027Potential Acquisition of a Consumer Health Portfolio60% success
• Q1 2027FDA Approval for a New Generic Product in the US Market70% success